Meta AnalysisID 6217
中成药治疗COVID-19的安全性和有效性：基于随机对照试验的系统评价与网状Meta分析。
CRD42022362499
Is proprietary Chinese medicine safe and effective in the treatment of COVID-19?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6217
- Evidence Id
- 14775
- Core Evidence Id
- 14775
- Source Meta Analysis Id
- 6198
- Herb2 Meta Analysis Id
- HBMA006198
- Crd Id
- CRD42022362499
- Title
- Safety and efficacy of Chinese patent medicine for COVID-19: a systematic review and network meta-analysis based on randomized controlled trials
- Review Question
- Is proprietary Chinese medicine safe and effective in the treatment of COVID-19?
- Study Type Included
- We will only include randomised controlled trials.
- Condition Being Studied
- COVID-19.
- Participant
- The population included patients diagnosed with COVID-19, regardless of gender, age, race, nationality, and other characteristics.
- Animal
- Human Disease Modelled
- Intervention
- The patients in treatment group must have been treated with a kind of Chinese patent medicine, including Jinhua Qinggan granule, Xuebiqing injection, Lianhua Qingwen capsule/granules, Huoxiang Zhengqi dripping pills, Toujie Quwen granules, Lianhua Qingke granules, Shuanghuanglian oral liquids, Shufeng Jiedu capsule.
- Comparator Control
- The treatment of control group was commonly used symptomatic medication such as antiviral, anti-infective, nutritional support drugs, or no treatment was given.
- Main Outcome
- 1. Clinical effective rate (rate of positive to negative for nucleic acid test); 2. Disappearance rate of main symptoms (including fever, fatigue, cough, etc.); 3. Occurrence rate of light or common type to severe form; 4. Mortality rate.
- Outcome Measure
- Additional Outcome
- 1. Improvement of secondary symptoms (chest pain, difficulty breathing, muscle ache, nausea, vomiting, diarrhea, etc); 2. Chest computed tomography (CT) imaging improvement; 3. Safety index, incidence of adverse events.
- Study Method
- Intervention, Network meta-analysis, Systematic review
- Keyword
- COVID-19; China; Humans; Medicine, Chinese Traditional; Network Meta-Analysis; Nonprescription Drugs; Randomized Controlled Trials as Topic
- Contact
- Wen Cao [email protected]
- Organisational Affiliation
- Lanzhou University Second Hospital
- Funding Source
- Not applicable
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-09-24
- Registration Date
- 2022-09-26
- Anticipated Start Date
- 2022-09-30
- Anticipated Completion Date
- 2023-04-10
- Title Cn
- 中成药治疗COVID-19的安全性和有效性：基于随机对照试验的系统评价与网状Meta分析。
- Title En
- Safety and efficacy of Chinese patent medicine for COVID-19: a systematic review and network meta-analysis based on randomized controlled trials
- Bilingual Status
- complete